Ligand id: 8000

Name: tabalumab

No information available.
Summary of Clinical Use
Click here to link to a list of the Phase 3 tabalumab trials registered with Efficacy and safety of tabalumab in SLE patients is reported in [4], results which indicate an improved response rate and a reduced frequency of flares in the treatment group receiving 120 mg every 2 weeks relative to placebo.
Mechanism Of Action and Pharmacodynamic Effects
BAFF acts as an immunostimulant, required for the formation, maintenance and survival of B cells [3], and is thus important for maintaining normal immunity. Over-production of BAFF is implicated in the abberant production of antibodies assocaiated with autoimmune conditions such as RA and systemic lupus erythmatosis. Tabalumab was predicted to limit the effect of abnormal BAFF secretion, reduce reactive antibody production and thereby improve disease symptoms.